Adjuvant systemic therapy protocol for Dukes' B2 and C resectable colon carcinoma

Area of Science:

• Oncology
• Clinical Trials
• Gastroenterology

Background:

• Adjuvant systemic therapy for high-risk colon cancer (Dukes' B2 and C) has utilized 5-fluorouracil (5-FU)-based regimens since the 1960s.
• Investigating novel combinations is crucial for improving treatment outcomes in locally advanced colon carcinoma.

Purpose of the Study:

• To compare the efficacy and toxicity of 5-fluorouracil (5-FU) plus leucovorin versus 5-FU plus alfa-2b interferon (IFN) as adjuvant therapy.
• To evaluate survival outcomes and adverse events in patients with resected colon adenocarcinoma.

Main Methods:

• A randomized study involving 322 patients with Dukes' stage B2 and C colon adenocarcinoma.
• Patients received either 5-FU/leucovorin for six cycles or 5-FU/IFN for six months.
• Outcomes assessed included disease-free survival and overall survival.

Main Results:

• No statistically significant difference in disease-free survival or overall survival was observed between the two treatment arms.
• Toxicity profiles were similar, except for a universal flu-like syndrome in the IFN-treated group.
• No patient subset demonstrated improved survival with the addition of IFN.

Conclusions:

• The combination of 5-FU and IFN does not offer survival advantages over 5-FU and leucovorin for adjuvant therapy in advanced colon cancer.
• The addition of IFN increases toxicity due to flu-like symptoms, making it an unfavorable option.
• Current data do not support the use of IFN in combination with 5-FU for adjuvant treatment of locally advanced colon carcinoma.